Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS27109
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CS27109 is a small molecule dual agonist of peroxisome proliferator-activated receptors alpha (PPARα) and delta (PPARδ), currently under development by Chipscreen Biosciences. It is primarily being investigated for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). By activating PPARα and PPARδ, the drug aims to modulate lipid metabolism, reduce inflammation, and improve insulin sensitivity, addressing the underlying metabolic dysregulation associated with fatty liver disease. As of the latest pipeline updates, CS27109 is in Phase 1 clinical development.
02
Targets
THRA (Thyroid hormone receptor alpha)THRB (Thyroid hormone receptor beta)
Beyond the preview
Go deeper on CS27109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS27109.